Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study-Reference-Cited by-同舟云学术

Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study

Published:2023-11 Issue:11 Volume:16 Page:
ISSN:1941-7640
Container-title:Circulation: Cardiovascular Interventions
language:en
Short-container-title:Circ: Cardiovascular Interventions

Author:

Tang Gilbert H.L.¹^ORCID,Spencer Julianne²,Rogers Toby³^ORCID,Grubb Kendra J.⁴⁵^ORCID,Gleason Patrick⁵⁶^ORCID,Gada Hemal⁷,Mahoney Paul⁸,Dauerman Harold L.⁹,Forrest John K.¹⁰^ORCID,Reardon Michael J.¹¹^ORCID,Blanke Philipp¹²,Leipsic Jonathon A.¹²,Abdel-Wahab Mohamed¹³^ORCID,Attizzani Guilherme F.¹⁴^ORCID,Puri Rishi¹⁵^ORCID,Caskey Michael¹⁶,Chung Christine J.¹⁷,Chen Ying-Hwa¹⁸^ORCID,Dudek Dariusz¹⁹,Allen Keith B.²⁰^ORCID,Chhatriwalla Adnan K.²⁰^ORCID,Htun Wah Wah²¹^ORCID,Blackman Daniel J.²²^ORCID,Tarantini Giuseppe²³^ORCID,Zhingre Sanchez Jorge²,Schwartz Greta²,Popma Jeffrey J.²,Sathananthan Janarthanan²⁴

Affiliation:

1. Department of Cardiovascular Surgery, Mount Sinai Health System, New York (G.H.L.T.).

2. Structural Heart & Aortic, Medtronic, Mounds View, MN (J. Spencer, J.Z.S., G.S., J.J.P.).

3. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington DC (T.R.).

4. Division of Cardiothoracic Surgery (K.J.G.), Emory University, Atlanta, GA.

5. Structural Heart and Valve Center (K.J.G., P.G.), Emory University, Atlanta, GA.

6. Division of Cardiology (P.G.), Emory University, Atlanta, GA.

7. University of Pittsburgh Medical Center Pinnacle Health, PA (H.G.).

8. Sentara Heart Hospital, Norfolk, VA (P.M.).

9. University of Vermont Larner College of Medicine, Burlington (H.L.D.).

10. Division of Cardiology, Yale School of Medicine, New Haven, CT (J.K.F.).

11. Department of Cardiovascular Surgery, Houston Methodist, TX (M.J.R.).

12. Center for Heart Valve Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada (P.B., J.A.L.).

13. Heart Center Leipzig at University of Leipzig, Germany (M.A.-W.).

14. Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, OH (G.F.A.).

15. Cleveland Clinic, OH (R.P.).

16. Abrazo Arizona Heart Hospital, Phoenix (M.C.).

17. Division of Cardiology, University of Washington Medical Center, Seattle (C.J.C.).

18. Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taiwan (Y.-H.C.).

19. Jagiellonian University Medical College, Krakow, Poland (D.D.).

20. St. Luke’s Mid America Heart Institute, Kansas City, MO (K.B.A., A.K.C.).

21. Gundersen Health System, La Crosse, WI (W.W.H.).

22. Department of Cardiology, Leeds Teaching Hospitals, Leeds, United Kingdom (D.J.B.).

23. Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Italy (G.T.).

24. Center for Heart Valve Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada (J. Sathananthan).

Abstract

BACKGROUND: Coronary accessibility following redo–transcatheter aortic valve replacement (redo-TAVR) is increasingly important, particularly in younger low-risk patients. This study aimed to predict coronary accessibility after simulated Sapien-3 balloon-expandable valve implantation within an Evolut supra-annular, self-expanding valve using pre-TAVR computed tomography (CT) imaging. METHODS: A total of 219 pre-TAVR CT scans from the Evolut Low-Risk CT substudy were analyzed. Virtual Evolut and Sapien-3 valves were sized using CT-based diameters. Two initial Evolut implant depths were analyzed, 3 and 5 mm. Coronary accessibility was evaluated for 2 Sapien-3 in Evolut implant positions: Sapien-3 outflow at Evolut node 4 and Evolut node 5. RESULTS: With a 3-mm initial Evolut implant depth, suitable coronary access was predicted in 84% of patients with the Sapien-3 outflow at Evolut node 4, and in 31% of cases with the Sapien-3 outflow at Evolut node 5 ( P <0.001). Coronary accessibility improved with a 5-mm Evolut implant depth: 97% at node 4 and 65% at node 5 ( P <0.001). When comparing 3- to 5-mm Evolut implant depth, sinus sequestration was the lowest with Sapien-3 outflow at Evolut node 4 (13% versus 2%; P <0.001), and the highest at Evolut node 5 (61% versus 32%; P <0.001). CONCLUSIONS: Coronary accessibility after Sapien-3 in Evolut redo-TAVR relates to the initial Evolut implant depth, the Sapien-3 outflow position within the Evolut, and the native annular anatomy. This CT-based quantitative analysis may provide useful information to inform and refine individualized preprocedural CT planning of the initial TAVR and guide lifetime management for future coronary access after redo-TAVR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02701283.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Leaflet and Neoskirt Height in Transcatheter Heart Valves

2. Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction

3. Risk of Coronary Obstruction Due to Sinus Sequestration in Redo Transcatheter Aortic Valve Replacement

4. Feasibility of Repeat TAVR After SAPIEN 3 TAVR

5. Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-Risk Patients With Severe Aortic Stenosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of bicuspid aortic valve disease in the transcatheter aortic valve implantation era;Heart;2024-08-07

2. Challenges in Coronary Access After Valve-in-Valve Transcatheter Aortic Valve Replacement: Is Bench Testing Part of the Solution?;Canadian Journal of Cardiology;2024-08

3. Impact of leaflet splitting on coronary access after redo-TAVI for degenerated supra-annular self-expanding platforms;EuroIntervention;2024-06

4. Transcatheter Aortic Valve Implantation to Treat Degenerated Aortic, Mitral and Tricuspid Bioprosthesis;Journal of Clinical Medicine;2024-01-19

5. CT Simulation for Redo-TAVR: Can We Predict Future Coronary Access?;Circulation: Cardiovascular Interventions;2023-11